NXP900 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: June 2, 2026

The clinical evidence base for NXP900 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung. Most recent publication: The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas., J Biol Chem, 2024.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas.
Dash S, Hanson S, King B, et al. · J Biol Chem · 2024
PubMed: PMID 39089584 · NCT05873686 · Carcinoma, Non-Small-Cell Lung

Publications by year

2024–2024: 1 publications.

2024

Publications by indication

Carcinoma, Non-Small-Cell Lung (1)

The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas.
J Biol Chem · 2024 · PMID 39089584 · NCT05873686

Publications by journal

J Biol Chem1 paper

All NXP900 publications (1)

2024 (1 paper)

The SRC family kinase inhibitor NXP900 demonstrates potent antitumor activity in squamous cell carcinomas.
Dash S, Hanson S, King B, et al. · J Biol Chem · 2024 · Derived
PubMed: PMID 39089584 · NCT05873686 · Carcinoma, Non-Small-Cell Lung

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 02 Jun 2026 17:40:17 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).